Arrowhead Pharmaceuticals took a tumble midday Friday following a research downgrade that argued the stock is now fairly valued.
Arrowhead (NASDAQ:ARWR) shares sank about 6%.
Cantor Fitzgerald cut the stock to neutral from overweight, leaving its price target at $24.
It’s time for shares to take a breather after a two-rally that’s seen the stock rocket about 1,700% higher, Cantor Fitzgerald argued.
Last month the stock was added to the S&P 600 Small Cap.
